ASCO与OH联合指南更新:驱动基因阳性IV期非小细胞肺癌的系统治疗
新推荐包括奥希替尼为EGFR突变(19外显子缺失、21外显子L858R及20外显子T790M)的最佳一线治疗,阿来替尼或布加替尼为ALK融合的最佳一线治疗,并首次纳入RET、MET和NTRK alteration的推荐。
要点
- 所有非鳞NSCLC患者应在治疗前检测可靶向的驱动基因,无论吸烟状态。
- ROS1融合、BRAF V600E突变、RET融合、MET外显子14跳跃突变及NTRK融合可用相应靶向治疗。
- EGFR突变一线首选奥希替尼;ALK融合一线首选阿来替尼或布加替尼。
核心结论
- 驱动基因阳性的IV期NSCLC患者应基于检测结果接受靶向治疗,化疗在多数阶段仍为选择。
研究设计与样本
- ASCO与Ontario Health(Cancer Care Ontario)NSCLC专家小组基于系统综述更新推荐。
主要发现
- 更新反映了自上一版以来证据的变化,关注结局包括疗效和安全性。
- 新增或修订推荐涉及EGFR、ALK、ROS1、BRAF、RET、MET和NTRK alteration的治疗选择。
关键数值与推荐
- 所有非鳞NSCLC患者应在实施晚期肺癌治疗前检测潜在可靶向突变,无论吸烟状态。
- ROS1融合、BRAF V600E突变、RET融合、MET外显子14跳跃突变和NTRK融合的靶向治疗可作为一线或二线选择。
- 奥希替尼是EGFR激活突变(19外显子缺失、21外显子L858R和20外显子T790M)的最佳一线治疗。
- 阿来替尼或布加替尼是ALK融合的最佳一线治疗。
- 指南首次纳入RET、MET和NTRK alteration的推荐。
临床怎么用
- 治疗前应遵循其他高质量检测指南,尽可能完成驱动基因检测。
- 根据检测到的驱动基因选择相应靶向治疗,化疗在多数阶段仍为可选方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To provide evidence-based recommendations updating the 2017 ASCO guideline on systemic therapy for patients with stage IV non-small-cell lung cancer (NSCLC) with driver alterations. A guideline update for systemic therapy for patients with stage IV NSCLC without driver alterations was published separately. METHODS: The American Society of Clinical Oncology and Ontario Health (Cancer Care Ontario) NSCLC Expert Panel updated recommendations based on a systematic review of randomized controlled trials (RCTs) from December 2015 to January 2020 and meeting abstracts from ASCO 2020. RESULTS: This guideline update reflects changes in evidence since the previous update. Twenty-seven RCTs, 26 observational studies, and one meta-analysis provide the evidence base (total 54). Outcomes of interest included efficacy and safety. Additional literature suggested by the Expert Panel is discussed. RECOMMENDATIONS: All patients with nonsquamous NSCLC should have the results of testing for potentially targetable mutations (alterations) before implementing therapy for advanced lung cancer, regardless of smoking status recommendations, when possible, following other existing high-quality testing guidelines. Most patients should receive targeted therapy for these alterations: Targeted therapies against ROS-1 fusions, BRAF V600e mutations, RET fusions, MET exon 14 skipping mutations, and NTRK fusions should be offered to patients, either as initial or second-line therapy when not given in the first-line setting. New or revised recommendations include the following: Osimertinib is the optimal first-line treatment for patients with activating epidermal growth factor receptor mutations (exon 19 deletion, exon 21 L858R, and exon 20 T790M); alectinib or brigatinib is the optimal first-line treatment for patients with anaplastic lymphoma kinase fusions. For the first time, to our knowledge, the guideline includes recommendations regarding RET, MET, and NTRK alterations. Chemotherapy is still an option at most stages.Additional information is available at www.asco.org/thoracic-cancer-guidelines.
引用
- Hanna NH, Robinson AG, Temin S, et al. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. J Clin Oncol. 2021. PMID: 33591844. doi:10.1200/JCO.20.03570
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。